I would hope the answer to the question posed in the title is a universal ‘yes’; at least that is my experience with this complex and common disease. The concept that in 2019, we have unmet needs in prostate cancer diagnostics is somewhat remarkable, given that we have access to: (i) one of the most […]
BAUS Day 3—Going home images and snippets… On the final night of BAUS, I had the honor of giving a dinner talk to the IBUS group—International British Urology Society. With BAUS contracting from 4 to 3 days, some of the previous joint sessions fell by the wayside, but IBUS president Subu Subramonian put together a […]
Achieving the Promise of Digital Health: Are we There Yet? If Not, When…and How? Dr. Robert Wachter Day 2: The 2018 BJUI Guest Lecture: Dr. Robert Wachter. Achieving the Promise of Digital Health: Are we There Yet? If Not, When…and How? Image 1: Q&A with Dr. Robert Wachter, moderated by BJUI Trustee Chair, Prof. Krishna […]
BAUS Day 2. The Multidisciplinary Team Debate. Which way are you headed? BAUS is certainly a UK-centric meeting. But we all share most of the same challenges in healthcare, and as an international urologist in attendance, the learning experience is often gaining insight into how different health systems tackle common problems with solutions and evolutions. […]
Day one at BAUS gets started with society meetings and the John Blandy Prize and Lecture delivered by Editor Prokar Dasgupta. The winner was from Pisano et al from Turin, Italy on “The role of re-transurethral resection in the management of high risk NMIBC (PMID 26469362). But I had to miss this event as I […]
It should surprise no one that I never agreed with the 2012 United States Preventive Services Task Force to give PSA a “D” rating that has led to decreases in U.S. rates of PSA testing, biopsies, and diagnosis of low- through high-risk cancer. I take care of men with prostate cancer in a multidisciplinary clinic […]
The BJUI supports clinical trials. Plain, simple, and with some new strategies. Randomised clinical trials (RCTs) are the highest level of evidence-based medicine. We know this to be true, but we also know that RCTs are a challenge to fund, accrue patients, execute, and follow to endpoints. From a statistician’s point of view, RCTs provide […]
In this month’s issue of the BJUI, we highlight the evolving era of immunotherapy in solid tumour therapy. As urological surgeons, we spend a large portion of our time working with anatomy, instruments, and robots – things we can see, touch, and control. Immunotherapy is a different conversation – cartoon pathways, process blockades, molecular expression […]
Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: a step-by-step guide to exposure and efficiency Stephen B. Williams, Yasar Bozkurt , Mary Achim, Grace Achim and John W. Davis Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA OBJECTIVE To describe a novel, step-by-step approach to […]
Intraoperative in vivo tracking of a periprostatic nerve with multiphoton microscopy in rat model. In the last 6 months, the BJUI editorial team has evaluated an average of 59 urological oncology papers per month with an average acceptance rate of 16%. We receive additional papers for our ‘Translational Science’ section. Studies with high-quality methods are given […]